Quantbot Technologies LP Decreases Holdings in Insulet Corporation $PODD

Quantbot Technologies LP lowered its position in Insulet Corporation (NASDAQ:PODD) by 31.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 26,581 shares of the medical instruments supplier’s stock after selling 12,231 shares during the quarter. Quantbot Technologies LP’s holdings in Insulet were worth $8,206,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Aster Capital Management DIFC Ltd boosted its stake in shares of Insulet by 1,015.7% during the third quarter. Aster Capital Management DIFC Ltd now owns 2,979 shares of the medical instruments supplier’s stock valued at $920,000 after acquiring an additional 2,712 shares during the last quarter. Handelsbanken Fonder AB raised its stake in Insulet by 16.0% in the 3rd quarter. Handelsbanken Fonder AB now owns 21,016 shares of the medical instruments supplier’s stock valued at $6,488,000 after purchasing an additional 2,900 shares during the last quarter. Generali Investments Management Co LLC lifted its holdings in Insulet by 300.6% in the 3rd quarter. Generali Investments Management Co LLC now owns 701 shares of the medical instruments supplier’s stock valued at $216,000 after purchasing an additional 526 shares in the last quarter. Andra AP fonden boosted its stake in shares of Insulet by 50.0% during the 3rd quarter. Andra AP fonden now owns 86,400 shares of the medical instruments supplier’s stock worth $26,674,000 after purchasing an additional 28,800 shares during the last quarter. Finally, Diversify Wealth Management LLC grew its holdings in shares of Insulet by 5.6% during the third quarter. Diversify Wealth Management LLC now owns 4,782 shares of the medical instruments supplier’s stock worth $1,525,000 after buying an additional 254 shares in the last quarter.

Wall Street Analysts Forecast Growth

PODD has been the subject of a number of recent analyst reports. Jefferies Financial Group lifted their price objective on Insulet from $375.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. BTIG Research restated a “buy” rating and issued a $380.00 price target on shares of Insulet in a report on Wednesday, February 18th. Truist Financial cut their price objective on shares of Insulet from $390.00 to $360.00 and set a “buy” rating on the stock in a report on Thursday, February 19th. TD Cowen downgraded shares of Insulet from a “buy” rating to a “hold” rating and set a $294.00 target price for the company. in a report on Monday, January 26th. Finally, Royal Bank Of Canada upped their price target on shares of Insulet from $370.00 to $380.00 and gave the stock an “outperform” rating in a research report on Friday, November 21st. Twenty analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Insulet presently has an average rating of “Moderate Buy” and a consensus price target of $354.57.

Insulet Stock Down 1.9%

Shares of NASDAQ PODD opened at $246.61 on Friday. Insulet Corporation has a 1 year low of $230.05 and a 1 year high of $354.88. The firm has a market cap of $17.36 billion, a price-to-earnings ratio of 70.46, a PEG ratio of 1.50 and a beta of 1.41. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.15 and a current ratio of 2.81. The stock’s 50-day simple moving average is $268.21 and its 200-day simple moving average is $303.18.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 EPS for the quarter, beating analysts’ consensus estimates of $1.48 by $0.07. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The firm had revenue of $783.80 million during the quarter, compared to the consensus estimate of $768.31 million. During the same quarter in the prior year, the business posted $1.15 earnings per share. Insulet’s revenue for the quarter was up 31.2% on a year-over-year basis. As a group, equities analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insider Transactions at Insulet

In related news, Director Michael R. Minogue acquired 2,030 shares of Insulet stock in a transaction that occurred on Wednesday, February 25th. The stock was acquired at an average price of $246.23 per share, for a total transaction of $499,846.90. Following the transaction, the director directly owned 17,483 shares of the company’s stock, valued at $4,304,839.09. This trade represents a 13.14% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.39% of the stock is owned by corporate insiders.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.